Cargando…

Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration

BACKGROUND: The purpose of this study is to evaluate the influence of anti-vascular endothelial growth factor (VEGF) in the appearance or progression of epiretinal membranes (ERMs) in age-related macular degeneration (ARMD) and investigate confounding factors causing ERMs. METHODS: Seventy-six eyes...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hikari, Yoshida, Izumi, Sakamoto, Masashi, Maeno, Takatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080384/
https://www.ncbi.nlm.nih.gov/pubmed/33906612
http://dx.doi.org/10.1186/s12886-021-01944-0
_version_ 1783685414629933056
author Taniguchi, Hikari
Yoshida, Izumi
Sakamoto, Masashi
Maeno, Takatoshi
author_facet Taniguchi, Hikari
Yoshida, Izumi
Sakamoto, Masashi
Maeno, Takatoshi
author_sort Taniguchi, Hikari
collection PubMed
description BACKGROUND: The purpose of this study is to evaluate the influence of anti-vascular endothelial growth factor (VEGF) in the appearance or progression of epiretinal membranes (ERMs) in age-related macular degeneration (ARMD) and investigate confounding factors causing ERMs. METHODS: Seventy-six eyes that were treated for more than 36 months from the first anti-VEGF injection were assessed. Binary logistic regression analysis was performed between smoking, lens status, subretinal hemorrhage, posterior vitreous detachment (PVD) status, peripheral retinal degeneration, type of AMD, conditions of contralateral eye, and the number of injections as independent variables and appearance or progression of ERMs during 36 months as dependent variables. RESULTS: The presence of vitreomacular adhesion (VMA) or development of PVD during the observation period was significantly associated (Odds ratio [OR]: 5.77; 95% confidence interval [CI], 1.72–19.4; p = 0.005) with the appearance or progression of ERMs. Moreover, peripheral retinal degeneration was significantly associated (OR: 3.87; 95% CI, 1.15–13.0; p = 0.029). Injection number of anti-VEGF was not significantly associated (OR: 1.02; 95% CI, 0.90–1.16; p = 0.72). CONCLUSION: This study suggests possibilities that anti-VEGF injections alone are unable to cause the development of ERMs, that VMA or developing PVD has a prior impact on the developing ERMs in ARMD similar to that of idiopathic ERMs, and that peripheral retinal degenerations and vitreomacular adhesion were both related to ERMs development and pathogenesis of ARMD.
format Online
Article
Text
id pubmed-8080384
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80803842021-04-29 Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration Taniguchi, Hikari Yoshida, Izumi Sakamoto, Masashi Maeno, Takatoshi BMC Ophthalmol Research BACKGROUND: The purpose of this study is to evaluate the influence of anti-vascular endothelial growth factor (VEGF) in the appearance or progression of epiretinal membranes (ERMs) in age-related macular degeneration (ARMD) and investigate confounding factors causing ERMs. METHODS: Seventy-six eyes that were treated for more than 36 months from the first anti-VEGF injection were assessed. Binary logistic regression analysis was performed between smoking, lens status, subretinal hemorrhage, posterior vitreous detachment (PVD) status, peripheral retinal degeneration, type of AMD, conditions of contralateral eye, and the number of injections as independent variables and appearance or progression of ERMs during 36 months as dependent variables. RESULTS: The presence of vitreomacular adhesion (VMA) or development of PVD during the observation period was significantly associated (Odds ratio [OR]: 5.77; 95% confidence interval [CI], 1.72–19.4; p = 0.005) with the appearance or progression of ERMs. Moreover, peripheral retinal degeneration was significantly associated (OR: 3.87; 95% CI, 1.15–13.0; p = 0.029). Injection number of anti-VEGF was not significantly associated (OR: 1.02; 95% CI, 0.90–1.16; p = 0.72). CONCLUSION: This study suggests possibilities that anti-VEGF injections alone are unable to cause the development of ERMs, that VMA or developing PVD has a prior impact on the developing ERMs in ARMD similar to that of idiopathic ERMs, and that peripheral retinal degenerations and vitreomacular adhesion were both related to ERMs development and pathogenesis of ARMD. BioMed Central 2021-04-28 /pmc/articles/PMC8080384/ /pubmed/33906612 http://dx.doi.org/10.1186/s12886-021-01944-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Taniguchi, Hikari
Yoshida, Izumi
Sakamoto, Masashi
Maeno, Takatoshi
Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title_full Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title_fullStr Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title_full_unstemmed Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title_short Epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
title_sort epiretinal membrane appearance or progression after intravitreal injection in age-related macular degeneration
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080384/
https://www.ncbi.nlm.nih.gov/pubmed/33906612
http://dx.doi.org/10.1186/s12886-021-01944-0
work_keys_str_mv AT taniguchihikari epiretinalmembraneappearanceorprogressionafterintravitrealinjectioninagerelatedmaculardegeneration
AT yoshidaizumi epiretinalmembraneappearanceorprogressionafterintravitrealinjectioninagerelatedmaculardegeneration
AT sakamotomasashi epiretinalmembraneappearanceorprogressionafterintravitrealinjectioninagerelatedmaculardegeneration
AT maenotakatoshi epiretinalmembraneappearanceorprogressionafterintravitrealinjectioninagerelatedmaculardegeneration